DGAP-News: Carl Zeiss Meditec AG / Key word(s): Quarterly / Interim Statement/Quarter Results Carl Zeiss Meditec AG grows, boosted by currency tailwinds / Strongest growth once again in Surgical Ophthalmology 12.02.2016 / 07:00 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Carl Zeiss Meditec AG grows, boosted by currency tailwinds / Strongest growth once again in Surgical Ophthalmology Revenue increases by 8.9 percent (adjusted for currency effects: 3.8 percent) to EUR 262.6 million in the first quarter of the fiscal year / EBIT margin reaches 12.3 percent JENA, 12 February 2016 The first three months of fiscal year 2015/16 were successful overall for Carl Zeiss Meditec AG: Boosted by a favorable development of the most important currencies, the medical technology company generated revenue of EUR 262.6 million (prior year: EUR 241.1 million); earnings before interest and tax (EBIT) increased by 15.6 percent year-on-year, to EUR 32.2 million, corresponding to an EBIT margin of 12.3 percent (prior year: 11.6 percent). Revenue from the three reporting regions and strategic business units grew further in the reporting currency during the first quarter Currency effects also affected earnings per share at the beginning of the year: due primarily to the negative results from currency hedges, which are offset by positive effects in the operating result, consolidated profit after non-controlling interests amounted to around EUR 16.7 million, corresponding to a decline of 8.8 percent compared with the year-ago figure. "The quarter was characterized by positive currency effects and, within the regions, by very heterogeneous development. Thanks to our balanced presence, we achieved a good overall result once again," says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. "Unlike other industries, we can also report largely stable development, for the time being, in our high-growth business in China." Key figures by business segment at a glance Once again, the Surgical Ophthalmology strategic business unit (SBU) achieved the highest growth rates. Revenue climbed by 13.6 percent in the reporting period, compared with the year-ago quarter, to EUR 92.6 million (prior year: EUR 81.6 million). Even after adjustment for currency effects, this growth was still in the double digits, at 10.7 percent. Surgical workstations for optimized workflow in ophthalmology, and intraocular lenses, were once again in high demand, as were systems for optical biometry. The Ophthalmic Systems SBU increased its revenue by 7.5 percent in the reporting period, to EUR 98.6 million (prior year: EUR 91.7 million). After adjustment for currency effects, however, this growth would only have amounted to 0.7 percent. The Microsurgery SBU generated revenue of EUR 71.3 million, which corresponds to an increase of 5.2 percent compared with the year-ago figure of EUR 67.8 million; adjusted for currency effects, revenue is on a par with the prior year. Revenue by region The three global regions made varying contributions to the Company's revenue; once again, the greatest growth came from the Asia/Pacific (APAC) region, even after adjusting for currency effects. In the EMEA region (Europe, Middle East and Africa), significant contributions to growth came in particular from Germany and the United Kingdom; development in Southern Europe was mixed. On balance, revenue in the EMEA region increased by 4.2 percent, to EUR 90.2 million (prior year: EUR 86.5 million). Revenue in the Americas region benefited from the strong U.S. dollar and - even on a currency-adjusted basis - from a positive trend in Latin America. Overall, revenue growth of 10.1 percent to EUR 88.8 million was achieved (prior year: EUR 80.6 million). Adjusted for currency effects, the region would have recorded a slight decline of 1.4 percent, because the development of the U.S. business remained subdued. The APAC region once again recorded the highest growth, increasing its revenue by 13.1 percent, to EUR 83.6 million (prior year: EUR 73.9 million). After adjustment for currency effects, this corresponds to growth of 9.1%. According to President and CEO, Dr. Ludwin Monz, the first quarter has not changed expectations for the fiscal year: "We shall continue to strive for growth that is at least on a par with market growth, and for an EBIT margin in the range of 13 to 15 percent." Revenue by strategic business unit

Figures in   3 Months  3 Months  Change from  Change from prior year
EUR'000      2014/15   2015/16   prior year   (adjusted for currency
                                              effects)





Ophthalmic
Systems      91,742    98,634    + 7.5%       + 0.7%



Surgical
Ophthalmol-
ogy          81,570    92,644    + 13.6%      + 10.7%





Microsurgery 67,778    71,323    + 5.2%       - 0.1%

Revenue by region

Figures in 3 Months  3 Months  Change from  Change from prior year(adjusted
EUR'000    2014/15   2015/16   prior year   for currency effects)


EMEA       86,549    90,195    + 4.2%       + 4.5%


Americas   80,639    88,815    + 10.1%      -1.4%


APAC       73,902    83,591    + 13.1%      + 9.1%

Contact for the press Jann Gerrit Ohlendorf, Director Communications, Carl Zeiss Meditec AG Phone: +49 (0)3641 220-331, Email: [email protected] Contact for investors Sebastian Frericks, Director Investor Relations, Carl Zeiss Meditec AG Phone: +49 (0)3641 220-116, Email: [email protected] http://www.zeiss.de/med/presse --------------------------------------------------------------------------- 12.02.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: Carl Zeiss Meditec AG Göschwitzer Str. 51-52 07745 Jena Germany Phone: +49 (0)3641 220-0 Fax: +49 (0)3641 220-112 E-mail: [email protected],[email protected] Internet: www.meditec.zeiss.de ISIN: DE0005313704 WKN: 531370 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart End of News DGAP News Service --------------------------------------------------------------------------- 436805 12.02.2016